Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain.
This pilot study examined the effect of a low-dose E and pulsed progestogen hormone therapy (HT) regimen for add-back during long-term GnRH-agonist therapy on bone mineral density (BMD) in five patients with stage IV endometriosis. Bone mineral density was stable after initiation of HT for the entire follow-up period (up to 10 years). One patient stopped her treatment on two occasions to conceive and was successful each time with delivery of a normal baby. No patient had return of pelvic pain after HT add-back.
Bedaiwy
Mohamed A
MA
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Toronto, and the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Casper
Robert F
RF
D000328:Adult; D018488:Bone Demineralization, Pathologic / Q000139:chemically induced* / Q000517:prevention & control*; D015519:Bone Density / Q000187:drug effects; D002908:Chronic Disease; D004338:Drug Combinations; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy*; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D017699:Pelvic Pain / Q000209:etiology / Q000517:prevention & control*; D010865:Pilot Projects; D011372:Progestins / Q000008:administration & dosage*; D016896:Treatment Outcome
D004338:Drug Combinations; D005300:Fertility Agents, Female; D011372:Progestins; D004958:Estradiol; D016729:Leuprolide